Literature DB >> 8653378

Cell kinetics in vivo of human breast cancer.

P D Stanton1, T G Cooke, G Forster, D Smith, J J Going.   

Abstract

Rates of cell proliferation within tumours may provide prognostic information and help in the rational administration of chemotherapy and radiotherapy. In vivo labelling with 5-bromo-2'-deoxyuridine (BrdU) was used in 89 women with breast cancer to determine the labelling index for BrdU (BLI), the length of S phase (TS) and the potential doubling time of the tumour (Tpot). Kinetic data were obtained in 84 patients. The median BLI was 3.2 per cent, TS 12 h, and Tpot 12.5 days. There was no systematic difference in the labelling index determined by flow cytometry and by manual counting on sections. Labelling indices were significantly higher in aneuploid tumours, and in tumours not expressing oestrogen receptors, but were not correlated with tumour size, nodal status, or expression of c-erbB2. In vivo measurement of tumour cell kinetics can be made rapidly and reliably in the majority of human breast cancers, and may have a role to play in planning therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8653378     DOI: 10.1002/bjs.1800830130

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  7 in total

1.  Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.

Authors:  G Wani; I Noyes; G E Milo; S M D'Ambrosio
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

Review 2.  Determinants and clinical implications of chromosomal instability in cancer.

Authors:  Laurent Sansregret; Bart Vanhaesebroeck; Charles Swanton
Journal:  Nat Rev Clin Oncol       Date:  2018-01-03       Impact factor: 66.675

3.  Early and multiple origins of metastatic lineages within primary tumors.

Authors:  Zi-Ming Zhao; Bixiao Zhao; Yalai Bai; Atila Iamarino; Stephen G Gaffney; Joseph Schlessinger; Richard P Lifton; David L Rimm; Jeffrey P Townsend
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

4.  Comparison of Acute and Late Toxicity of Two Regimens of 3- and 5-Week Concomitant Boost Prone IMRT to Standard 6-Week Breast Radiotherapy.

Authors:  Shahzad Raza; Stella C Lymberis; Raquel Ciervide; Deborah Axelrod; Maria Fenton-Kerimian; Chiara Magnolfi; Barry Rosenstein; J Keith Dewyngaert; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-05-08       Impact factor: 6.244

5.  Evaluation of the interfractional biological effective dose (BED) variation in MammoSite high dose rate brachytherapy.

Authors:  Yongbok Kim; E Day Werts; Mark G Trombetta; Moyed Miften
Journal:  J Appl Clin Med Phys       Date:  2010-06-10       Impact factor: 2.102

6.  Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.

Authors:  Sian M Tovey; Caroline J Witton; John M S Bartlett; Peter D Stanton; Jonathan R Reeves; Timothy G Cooke
Journal:  Breast Cancer Res       Date:  2004-03-23       Impact factor: 6.466

7.  Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells.

Authors:  Keith M Gligorich; Rachel M Vaden; Dawne N Shelton; Guoying Wang; Cindy B Matsen; Ryan E Looper; Matthew S Sigman; Bryan E Welm
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.